ArticleMolecular psychiatry2026
Molecular alterations in chondrolectin-containing somatostatin neurons in schizophrenia differ based on circuit context.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Alterations in cortical somatostatin (SST)-containing GABAergic interneurons are among the most consistently replicated molecular findings in schizophrenia. Whether these alterations primarily reflect intrinsic cellular vulnerabilities, regional circuit context, or an interaction between the two remains unclear. To address this question, we examined a transcriptionally distinct SST neuron subtype that selectively expresses chondrolectin (CHODL), referred to as CHODL-SST neurons, across two brain regions with markedly different circuit organization: deep layer 6 and adjacent subcortical white matter of the dorsolateral prefrontal cortex (DLPFC) and the caudate nucleus.Using multiplex fluorescent in situ hybridization in postmortem tissue from 18 matched pairs of schizophrenia and unaffected comparison individuals, we quantified mRNA levels of CHODL, SST, neuropeptide Y (NPY), and nitric oxide synthase (NOS1) within CHODL-SST neurons in both regions.In the DLPFC, CHODL-SST neurons exhibited lower mRNA levels for all four transcripts in schizophrenia, with small-to-medium effect sizes (-0.29 to -0.52). In contrast, effect sizes in the caudate were nominal (-0.13 to 0.03), with Bayesian analyses providing strong evidence for no difference in schizophrenia. For every transcript, a significant diagnosis-by-region interaction (all p < 0.005) highlighted a striking dissociation between cortical and striatal CHODL-SST neurons.These findings indicate that schizophrenia-associated molecular alterations in CHODL-SST neurons are regionally selective and preferentially affect cortical populations. Rather than reflecting uniform cell-intrinsic vulnerability, these results support a model in which differential vulnerability emerges from the interaction between subtype-specific molecular features and regional circuit context, with implications for understanding SST neuron dysfunction and developing circuit-informed therapeutic strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.